ImmuPharma not buried yet by lead program's trial failure

19 April 2018

Specialist UK drug company ImmuPharma (LSE:IMM) suffered a predictably brutal share market loss of 77% on Tuesday on the back of the publication of trial results for its lupus candidate Lupuzor (forigerimod).

The Phase III trial did not meet its primary endpoint but the company has blamed this on the placebo-effect and stressed that Lupuzor warrants continued investigation.

Lupuzor demonstrated a superior response rate over placebo of 68.8% to 59.2% in the 153 patients who completed the study, and the difference was more significant among those who had anti-dsDNA autoantibodies, a recognized biomarker for systemic lupus erythematosus. Some 7.6% of these patients in the Lupuzor group went into full remission versus none in the placebo group. There were no adverse events reported.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK